Urotensin II inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating ATF expression and via the ERK and Akt pathway

PLoS One. 2014 Sep 30;9(9):e106812. doi: 10.1371/journal.pone.0106812. eCollection 2014.

Abstract

Background and purpose: Regulation of the homeostasis of vascular endothelium is critical for the processes of vascular remodeling and angiogenesis under physiological and pathological conditions. Urotensin II (U-II), a potent vasoactive peptide, participates in vascular and myocardial remodeling after injury. We investigated the protective effect of U-II on doxorubicin (DOX)-induced apoptosis in cultured human umbilical vein endothelial cells (HUVECs) and the potential mechanisms involved in this process.

Experimental approach: Cultured HUVECs were treated with vehicle, DOX (1 µM), U-II, or U-II plus DOX. Apoptosis was evaluated by DNA strand break level with TdT-mediated dUTP nick-end labeling (TUNEL) staining. Western blot analysis was employed to determine the related protein expression and flow cytometry assay was used to determine the TUNEL positive cells.

Key results: U-II reduced the quantity of cleaved caspase-3 and cytosol cytochrome c and increased Bcl-2 expression, which results in protecting HUVECs from DOX-induced apoptosis. U-II induced Activating transcription factor 3 (ATF3) at both mRNA and protein levels in U-II-treated cells. Knockdown of ATF3 with ATF3 siRNA significantly reduced ATF3 protein levels and U-II protective effect under DOX-treated condition. U-II downregulated p53 expression in DOX-induced HUVECs apoptosis, and it rapidly activated extracellular signal-regulated protein kinase (ERK) and Akt. The DOX induced change of p53 was not affected by U-II antagonist (urantide) under ATF-3 knockdown. The inhibitory effect of U-II on DOX-increased apoptosis was attenuated by inhibitors of ERK (U0126) and PI3K/Akt (LY294002).

Conclusion and implications: Our observations provide evidence that U-II protects HUVECs from DOX-induced apoptosis. ERK-Akt phosphorylation, ATF3 activation, and p53 downregulation may play a signal-transduction role in this process.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Activating Transcription Factor 3 / genetics
  • Activating Transcription Factor 3 / metabolism*
  • Antibiotics, Antineoplastic / pharmacology*
  • Apoptosis / drug effects
  • Cell Survival / drug effects
  • Cells, Cultured
  • Doxorubicin / pharmacology*
  • Gene Expression / drug effects
  • Human Umbilical Vein Endothelial Cells / physiology*
  • Humans
  • MAP Kinase Signaling System
  • Phosphatidylinositol 3-Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Tumor Suppressor Protein p53 / metabolism
  • Urotensins / physiology*

Substances

  • ATF3 protein, human
  • Activating Transcription Factor 3
  • Antibiotics, Antineoplastic
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Urotensins
  • Doxorubicin
  • urotensin II
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt

Grants and funding

This study was supported by grants from the National Science Council Foundation (NSC103-2314-B-016-022-MY3 and NSC101-2314-B-016-007-MY2; DV103-04), National Defense Medical Bureau (DOD102-I-30; D103-M084), and Tri-Service General Hospital (TSGH-C103-028; TSGH-C102-028), Taipei, Taiwan, Republic of China to SH Loh and CS Tsai. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.